Sensitization of human Ewing's tumor cells to chemotherapy and heat treatment by the bioflavonoid quercetin

Anticancer Research

Volumn 23, Issue 4, 2003, Pages 3359-3366

  Debes, Anette ^a   Oerding, Matthias ^a   Willers, Reinhart ^a   Göbel, Ulrich ^a   Wessalowski, Rüdiger ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Ewing's tumor; HSP27; HSP70; Quercetin; Thermotolerance

Indexed keywords

CISPLATIN; ETOPOSIDE; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; QUERCETIN;

ARTICLE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CELL SURVIVAL; CROSS LINKING; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; EWING SARCOMA; HEAT SHOCK; HEAT TOLERANCE; HEAT TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; TEMPERATURE SENSITIVITY; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DRUG SYNERGISM; ETOPOSIDE; HEAT-SHOCK PROTEINS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; HYPERTHERMIA, INDUCED; NEOPLASM PROTEINS; QUERCETIN; SARCOMA, EWING'S; TUMOR CELLS, CULTURED;

EID: 0041528154     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Samali A, Holmberg CI, Sistonen L and Orrenius S: Thermotolerance and cell death are distinct cellular responses to stress: dependence on heat shock proteins. FEBS Lett 461: 306-310, 1999.
2. Gabai VL, Zamulaeva IV, Mosin AF, Makarova YM, Mosina VA, Budagova KR, Malutina YV and Kabakov AE: Resistance of Ehrlich tumor cells to apoptosis can be due to accumulation of heat shock proteins. FEBS Lett 375: 21-26, 1995.
3. Arrigo AP: Small stress proteins: chaperones that act as regulators of intracellular redox state and programmed cell death. Biol Chem 379: 19-26, 1998.
4. Craig EA: Chaperones: helpers along the pathways to protein folding. Science 260: 1902-1903, 1993.
5. Hartl FU: Molecular chaperones in cellular protein folding. Nature 381: 571-579, 1996.
6. Hertog MG, Hollman PC, Katan MB and Kromhout D: Intake of potentially anticarcinogenic flavonoids and their determinants in adults in The Netherlands. Nutr Cancer 20: 21-29, 1993.
7. Scalbert A and Williamson G: Dietary intake and bioavailability of polyphenols. J Nutr 130: 2073S-2085S, 2000.
8. Dockhorn-Dworniczak B, Schäfer KL, Dantcheva R, Blasius S, van Valen F, Burdach S, Winkelmann W, Jürgens H and B̈cker W: Molecular genetic detection of t(11;22)(q24;12) translocation in Ewing sarcoma and malignant peripheral neuroectodermal tumors. Pathologe 15: 103-112, 1994.
9. Henwood JM and Brogden RN: Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer. Drugs 39: 438-490, 1990.
10. Peng B, English MW, Boddy AV, Price L, Wyllie R, Pearson AD, Tilby MJ and Newell DR: Cisplatin pharmacokinetics in children with cancer. Eur J Cancer 33: 1823-1828, 1997.
11. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D and Boyd MR: Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48: 4827-4833, 1988.
12. Castillo MH, Perkins E, Campbell JH, Doerr R, Hassett JM, Kandaswami C and Middleton E: The effects of the bioflavonoid quercetin on squamous cell carcinoma of head and neck origin. Am J Surg 158: 351-355, 1989.
13. Yoshida M, Sakai T, Hosokawa N, Marui N, Matsumoto K, Fujioka A, Nishino H and Aoike A: The effect of quercetin on cell cycle progression and growth of human gastric cancer cells. FEBS Lett 260: 10-13, 1990.
14. Larocca LM, Ranelletti FO, Maggiano N, Rutella S, La Barbera EO, Rumi C, Serra F, Voso MT, Piantelli M, Teofili L and Leone G: Differential sensitivity of leukemic and normal hematopoietic progenitors to the killing effect of hyperthermia and quercetin used in combination: role of heat-shock protein-70. Int J Cancer 73: 75-83, 1997.
15. Piantelli M, Tatone D, Castrilli G, Savini F, Maggiano N, Larocca LM, Ranelletti FO and Natali PG: Quercetin and tamoxifen sensitize human melanoma cells to hyperthermia. Melanoma Res 11: 469-476, 2001.
16. Asea A, Ara G, Teicher BA, Stevenson MA and Calderwood SK: Effects of the flavonoid drug quercetin on the response of human prostate tumours to hyperthermia in vitro and in vivo. Int J Hyperthermia 17: 347-356, 2001.
17. Sliutz G, Karlseder J, Tempfer C, Orel L, Holzer G and Simon MM: Drug resistance against gemcitabine and topotecan mediated by constitutive hsp70 overexpression in vitro: implication of quercetin as sensitiser in chemotherapy. Br J Cancer 74: 172-177, 1996.
18. Scambia G, Ranelletti FO, Panici PB, De Vincenzo R, Bonanno G, Ferrandina G, Piantelli M, Bussa S, Rumi C, Cianfriglia M et al: Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol 34: 459-464, 1994.
19. Debes A, Rommel F, Breise M, Willers R, Göbel U and Wessalowski R: In vitro test-system for chemo- and thermosensitivity: an analysis of survival fractions and cell-cycle distributions in human Ewing's sarcomas as a model for tumors in pediatric oncology. Klin Pädiatr 214: 223-229, 2002.
20. Cipak L, Rauko P, Miadokova E, Cipakova I and Novotny L: Effects of flavonoids on cisplatin-induced apoptosis of HL-60 and L1210 leukemia cells. Leuk Res 27: 65-72, 2003.
21. Chan MM, Fong D, Soprano KJ, Holmes WF and Heverling H: Inhibition of growth and sensitization to cisplatin-mediated killing of ovarian cancer cells by polyphenolic chemopreventive agents. J Cell Physiol 194: 63-70, 2003.
22. Lee YJ, Erdos G, Hou ZZ, Kim SH, Kim JH, Cho JM and Corry PM: Mechanism of quercetin-induced suppression and delay of heat shock gene expression and thermotolerance development in HT-29 cells. Mol Cell Biochem 137: 141-154, 1994.
23. Wei YQ, Zhao X, Kariya Y, Fukata H, Teshigawara K and Uchida A: Induction of apoptosis by quercetin: involvement of heat shock protein. Cancer Res 54: 4952-4957, 1994.
24. Li GC, Mivechi NF and Weitzel G: Heat shock proteins, thermotolerance, and their relevance to clinical hyperthermia. Int J Hyperthermia 11: 459-488, 1995.
25. Jaattela M: Escaping cell death: survival proteins in cancer. Exp Cell Res 248: 30-43, 1999.
26. Ohtsuboa T, Kanob E, Uedac K, Matsumotob H, Saitoa T, Hayashib S, Hatashitab M, Jinb Z and Saitoa H: Enhancement of heat-induced heat shock protein (hsp)72 accumulation by doxorubicin (Dox) in vitro Cancer Lett 159: 49-55, 2000.
27. Matsumoto H, Hayashi S, Shioura H, Ohtsubo T, Kitai R, Ohnishi K, Hayashi N, Ohnishi T and Kano E: Suppression of heat-induced HSF activation by CDDP in human glioblastoma cells. Int J Radiat Oncol Biol Phys 41: 915-920, 1998.
28. Ferry DR, Smith A, Malkhandi J, Fyfe DW, deTakats PG, Anderson D, Baker J and Kerr DJ: Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 2: 659-668, 1996.